CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
Teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04026256
NCT04026256Phase 4Completed
CompareCT.gov

Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

Massachusetts General Hospital·interventional·Posted Jul 19, 2019·Updated Aug 2, 2023

In Brief

A Phase 4 clinical trial evaluating Teriparatide and Denosumab for Postmenopausal Osteoporosis. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJul 19, 2019
Enrollment StartSep 2, 2019
Primary CompletionApr 18, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.0 years ago

Interventions

Teriparatidedrug

teriparatide daily subcutaneous injection

Denosumabdrug

denosumab subcutaneous injection